Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Sally E. Blount is Director at Abbott Laboratories. OQRO lists 2 transactions filed with the SEC under this name, the latest on Apr 28, 2026, each linked to the official Form 4.
Director
Disclosures on record
2
Companies involved
1
Abbott LaboratoriesABT
2 disclosures · May 2025 – Apr 2026 · 1 sold
Apr 24, 20262,286disclosed Apr 28
DetailsOfficial recordApr 30, 2025Sold~$337Kdisclosed May 2
DetailsOfficial recordAs of the latest filing on , Sally E. Blount reported holding 36,344 shares of Abbott Laboratories (ABT), worth about $3.81M at the last close of $105 (Nov 17, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Abbott Laboratories ABT | 36,344 | 36K direct | $105 | $3.81M | Apr 24, 2026 |
Is this Sally E. Blount’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Sally E. Blount bought shares on the open market in 2016 and 2020, and has not bought since 2020 across 2 companies. Sales in 2 of the 11 years since 2016.
Sally E. Blount reported 2 open-market purchases and 3 sales since 2016; purchases in 2 different years, most recently 2020.
| Year | Bought | Sold |
|---|---|---|
| 2025 | — | $337K1×1 trade |
| 2020 | $48K1×1 trade | — |
| 2019 | — | $332K2×2 trades |
| 2016 | $200K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Apr 24, 2026, Sally E. Blount reported holding 36,344 shares of Abbott Laboratories (ABT). At the last close of $105 on Nov 17, 2026, that is about $3.81M. This is the stake disclosed in filings, not a net worth.
Sally E. Blount bought shares on the open market in 2016 and 2020, and has not bought since 2020 across 2 companies. Sales in 2 of the 11 years since 2016.
In SEC filings since 2016: the latest open-market purchase is from 2020; the latest open-market sale is from 2025.
2 companies: Abbott Laboratories (ABT, 2016–2025), Ulta Beauty (ULTA, 2019–2020).
Sally E. Blount reported 1 open-market purchase and 2 sales here, 2016 to 2025.
Sally E. Blount reported 1 open-market purchase and 1 sale here, 2019 to 2020.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.